
==== Front
Gastro Hep Adv
Gastro Hep Adv
Gastro Hep Advances
2772-5723
Elsevier

S2772-5723(24)00069-4
10.1016/j.gastha.2024.05.003
Original Research—Clinical
Long-Term Neoplastic Risk Associated With Colorectal Strictures in Crohn’s Disease: A Multicenter Study
Hunaut Thomas thunaut@chu-reims.fr
1∗
Peyrin-Biroulet Laurent 23456
Le Bozec Antoine 7
Germain Adeline 8
Gower-Rousseau Corinne 9
Sabbagh Charles 1011
Cadiot Guillaume 1
Fumery Mathurin 12
1 Department of Gastroenterology, Reims University Hospital, Université de Champagne-Ardenne, Reims, France
2 Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France
3 INFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy, France
4 FHU-CURE, Nancy University Hospital, Vandœuvre-lès-Nancy, France
5 Groupe Hospitalier privé Ambroise Paré - Hartmann, Paris IBD Center, Neuilly sur Seine, France
6 Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada
7 Department of Pharmacy, Reims University Hospital, Université de Champagne-Ardenne, Reims, France
8 Department of Digestive Surgery, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France
9 Research and Public Health Unit, Reims University Hospital, Université de Champagne-Ardenne, Reims, France
10 Department of Digestive Surgery, CHU d'Amiens Picardie, Amiens Cedex 01, France
11 UR UPJV 7518, SSPC (Simplification of Surgical Patients Care), Université de Picardie Jules Verne, Amiens, France
12 Department of Gastroenterology, Amiens University Hospital, and PeriTox, Université de Picardie, Amiens, France
∗ Correspondence: Address correspondence to: Thomas Hunaut, MD, Department of Gastroenterology, Reims University Hospital, 45 rue Cognacq Jay, Reims 51100, France. thunaut@chu-reims.fr
16 5 2024
2024
16 5 2024
3 6 731737
5 1 2024
7 5 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Background and Aims

While the occurrence of colonic stricture in Crohn’s disease (CD) always raises concerns about the risk of cancer, the neoplastic risk associated with its stricture remains poorly known.

Methods

All consecutive patients with colorectal stricture complicating CD in 3 academic centers between 1993 and 2022 were included in a retrospective cohort. We collected clinical, endoscopic, surgical, and pathology data and information on outcomes. Factors associated with neoplastic stricture were investigated by logistic regression.

Results

A total of 88 patients (median age, 25 [interquartile range {IQR}, 19–37] years and median disease duration 12 [4–19] years) with 96 colorectal strictures were included. Strictures were nonpassable by the scope in 61.4% (n = 54) of cases, 70.5% (n = 62) were ulcerated, and 62.5% (n = 55) were symptomatic. Colonic resection and endoscopic balloon dilatation were needed in 47.7% (n = 42) and 28.6% (n = 12) of patients, respectively. After a median follow-up of 21.5 months (IQR [5.5–46.5]), 7 (8%) patients were diagnosed with neoplasia at the colonic stricture site (colonic adenocarcinoma, n = 5; neuroendocrine carcinoma, n = 1; and B-cell lymphoproliferative neoplasia, n = 1), with a median stricture duration at colorectal neoplasia diagnosis of 0 month (IQR [0.0–5.5]). While neoplastic strictures were diagnosed in older patients (58 vs 39 years), with longer disease duration (18 vs 11 years) and frequent obstructive symptoms (57.1% vs 11.1%), no patient-related or stricture-related factor was associated with neoplastic stricture in multivariate analysis.

Conclusion

Eight percent of patients with colonic stricture complicating CD developed colorectal cancer. Colorectal cancer and stricture were often diagnosed at the same time and we did not report malignant stricture after 1 year of follow-up.

Keywords

Crohn’s Disease
Colonic Stricture
Cancer
Abbreviations used in this paper

CD Crohn’s disease

CRC colorectal cancer

IQR interquartile range
==== Body
pmcIntroduction

Crohn’s disease (CD) is a chronic and progressive inflammatory disorder of the gastrointestinal tract that can lead to altered quality of life, disability, and irreversible bowel damage.1,2 CD is also associated with an increased risk of colorectal cancer (CRC). The incidence of CRC in CD has been evaluated between 75 and 82 per 100,000 person-years, with an increase of 40%–60% compared to the general population.3, 4, 5 Risk factors for CRC in inflammatory bowel disease include primary sclerosis cholangitis, family history of colonic cancer, personal history of colonic dysplasia, extensive colitis, pseudopolyps, disease duration over 8 years, and colorectal stricture.6, 7, 8, 9, 10, 11, 12, 13, 14 According to international recommendations, screening colonoscopy is recommended after 8 years of evolution, with timing intervals based on the presence of these factors.15

The prevalence of colonic stricture in CD has been evaluated between 8% and 13.5%.10, 11, 12, 13, 14,16 The occurrence of colonic stricture in CD always raises concerns about the risk for dysplasia/cancer. European Crohn's and Colitis Organisation (ECCO) guidelines recommended a colonoscopy at the diagnosis of colonic stricture with multiple biopsies followed by annual screening colonoscopy,13 but there is no consensus for the management of these strictures. Few studies with conflicting results have evaluated the frequency of CRC associated with colonic stricture in CD, and the natural history of colonic stricture in CD is poorly known. While the oldest study reported a CRC risk of 6.8%,10 the most recent found a risk of 0.32%.12 Moreover, negative endoscopic biopsies are insufficient to rule out neoplastic complication.16 Most of these studies are issued from single center, and were also characterized by a low number of included patients, and little information on clinical, endoscopic, and pathological findings.

Therefore, multicenter studies are needed to better understand the risk of colonic stricture-associated neoplasia and to identify CRC risk factors enabling personalized therapeutic strategies at the era of biologics and modern endoscopy.

Materials and Methods

Population

This retrospective cohort study was performed in 3 French referral centers (Amiens, Nancy, and Reims University Hospitals) having access to a clinical database including all consecutive adult patients with colonic stricture and CD between 1993 and 2022. Inclusion criteria were (1) age ≥18 years, (2) CD patient, and (3) colonic stricture. We included all patients with new stricture diagnosis which were then subsequently followed with surveillance. The follow-up began at the date of stricture diagnosis. Colonic stricture was defined as a narrowing of the colonic lumen in coloscopy. Anastomotic strictures, terminal ileum strictures, ileocecal valve strictures, and obvious polypoid lesions producing narrowing of the lumen were excluded.

Data Collection

Clinical, surgical, and pathological data were extracted from patient’s hospital medical records retrospectively, using a standardized questionnaire specifically developed for this study. The following clinical data were gender, age, age at CD diagnosis, history of colonic surgery, localization and phenotype according to Montreal classification,17 perianal disease, history of extra-intestinal autoimmune disease, history of primary sclerosing cholangitis, active smoking, personal history of colonic dysplasia, extensive colitis, familial history of CD or colonic cancer, and disease activity at time of surgery based on physicians’ judgment. The following information on colonic stricture was collected: age at diagnosis, disease duration at stricture diagnosis, localization, length (assessed by colonoscopy or cross-sectional imaging), symptomatic character (abdominal pain, constipation, subocclusive or occlusive syndrome), passable with the endoscope, and presence of ulceration. Follow-up was performed until date of death, stricture disappearance, or censored at December 31, 2022. Stricture-related symptoms and therapeutic and endoscopic outcomes were also collected. Presence of dysplasia (low-grade or high-grade dysplasia) or cancer (histological description) was also recorded whenever available.

Statistical Analysis

Quantitative variables were described as the mean ± standard deviation or median (interquartile range and minimum and maximum) according to the distribution of the variable, and qualitative variables were described as numbers and percentages. Results were analyzed using Student’s t-test (mean ± standard deviation comparison) and Fisher’s exact test (percentage comparison), respectively, to describe difference between both groups. Univariate logistic regression model was used to estimate the association between variables and CRC diagnosis. Multivariate logistic regression was achieved with stepwise backward procedure and adjusted on the variables included in the univariate analysis. All analyses were 2-tailed, and variables with P values <.05 were considered statistically significant. The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, and applicable regulatory requirements. The study was approved by local Ethics Committee (MR00429082023, “CHU de Reims”). All authors had access to the study data and reviewed and approved the final manuscript.

Results

Study Population

We identified 88 patients with a total of 96 colorectal strictures between 1993 and 2022. The main characteristics of the population are presented in Table 1. Fifty-three patients (60.2%) were female, the median age and disease duration at stricture diagnosis were 25 (IQR, 19–37) and 12 (IQR, 4–19) years, respectively. CD location at the diagnosis of colonic stricture according to the Montreal Classification was pure colonic disease (L2) in 42% (n = 37) and ileocolonic disease (L3) in 58% (n = 51) of cases. Respectively, 4.5% (n = 4) and 1.1% (n = 1) of patients had a personal or familial history of colonic dysplasia/CRC. One quarter (n = 21, 23.9%) of patients had a penetrating behavior associated to strictures and another quarter (n = 22, 25%) experienced a prior intestinal resection. Previous exposition to 5-aminosalicylates, azathioprine, anti-tumor necrosis factor, and other biologics were observed in 38.6%, 55.7%, 60.3%, and 12.5% of patients, respectively. Only 2 patients had history of primary sclerosis cholangitis (2.3%).Table 1 Characteristics of the Population at the Time of Colonic Stricture Diagnosis

Characteristics	Overall population
N = 88	Nonmalignant colorectal stricture
N = 81	Malignant colorectal stricture
N = 7	P value	
Female, n (%)	53 (60.2)	49 (60.5)	4 (57.1)	.99	
Age at CD diagnosis (median, IQR)	25.0 [19, 37]	25.0 [19, 37]	32.0 [27, 42]	.39	
Familial history of IBD (n, %)	8 (9.1)	8 (9.9)	0	.85	
Familial history of colorectal cancer, n (%)	1 (1.1)	1 (1.2)	0	.99	
Personal history of colonic dysplasia, n (%)	4 (4.5)	4 (4.9)	0	.99	
Personal history of intestinal resection for CD, n (%)	22 (25.0)	19 (24.5)	3 (42.9)	.36	
Disease topography				.99	
 L2, n (%)	37 (42.0)	34 (42.0)	3 (42.9)		
 L3, n (%)	51 (58.0)	47 (58.0)	4 (57.1)		
Disease phenotype				.87	
 B2, n (%)	67 (76.1)	61 (75.3)	6 (85.7)		
 B3, n (%)	21 (23.9)	20 (24.7)	1 (14.3)		
Perianal CD, n (%)	29 (33.0)	27 (33.3)	2 (28.6)	.99	
Extra-intestinal manifestations, n (%)	7 (8.0)	6 (7.4)	1 (14.3)	.45	
Active smoking, n (%)	16 (18.2)	16 (19.8)	0	.34	
Extensive colitis, n (%)	66 (75.0)	60 (74.1)	6 (85.7)	.67	
Primary sclerosis cholangitis, n (%)	2 (2.3)	1 (1.2)	1 (14.3)	.15	
Prior medication exposure					
 5-ASA, n (%)	34 (38.6)	33 (40.7)	1 (14.3)	.24	
 Thiopurines, n (%)	49 (55.7)	46 (56.8)	3 (42.9)	.70	
 Anti-TNFα, n (%)	53 (60.3)	49 (60.5)	4 (57.1)	.99	
 Vedolizumab, n (%)	5 (5.7)	5 (6.2)	0	.99	
 Ustekinumab, n (%)	6 (6.8)	4 (4.9)	2 (18.6)	.07	
 Other, n (%)	13 (14.8)	12 (14.8)	1 (14.3)	.99	
Age at stricture diagnosis (median, IQR)	41.00 [31, 54.75]	39.00 [30.5, 53]	58.00 [48.5, 59]	.03	
Disease duration before stricture diagnosis; y (median, IQR)	12.0 [4.0; 19.75]	11 [4.0; 19]	18.0 [11.5; 24.0]	.27	
Nonpassable stricture, n (%)	54 (61.4)	48 (59.3)	6 (85.7)	.09	
Localization				.01	
 Rectum, n (%)	8 (9.1)	5 (6.2)	3 (42.9)		
 Sigmoid, n (%)	25 (28.4)	25 (30.9)	0		
 Left colon, n (%)	29 (32.9)	26 (32.1)	3 (42.9)		
 Transverse colon, n (%)	13 (14.8)	13 (16.0)	0		
 Right colon, n (%)	11 (12.5)	10 (12.3)	1 (14.2)		
Occlusive and/or subocclusive syndrome, n (%)	13 (14.8)	9 (11.1)	4 (57.1)	<10−2	
Multiple strictures, n (%)	7 (8.0)	7 (8.6)	0	.99	
Colonoscopic aspect				.05	
 Nonulcerated, n (%)	15 (17.0)	15 (18.5)	0		
 Ulcerated, n (%)	62 (70.5)	58 (71.6)	4 (57.1)		
 Budding, n (%)	5 (5.7)	3 (3.7)	2 (28.7)		
Surgery				.60	
 Partial colectomy, n (%)	19 (45.2)	17 (47.2)	2 (33.3)		
 Total colectomy, n (%)	12 (28.6)	10 (27.8)	2 (33.3)		
 Coloproctectomy, n (%)	3 (7.1)	2 (5.6)	1 (16.7)		
 Other, n (%)	8 (19.1)	7 (19.4)	1 (16.7)		
Surgery indication				.30	
Occlusive syndrome, n (%)	13 (31.0)	10 (27.7)	3 (42.9)		
Dysplasia or neoplasia, n (%)	2 (4.8)	1 (2.8)	1 (16.7)		
Failure of medical treatment, n (%)	12 (28.6)	11 (30.6)	1 (16.7)		
Other, n (%)	14 (33.2)	13 (36.1)	1 (16.7)		
CD, Crohn’s disease; IBD, inflammatory bowel disease; IQR, interquartile range.

Stricture Characteristics and Their Management

Strictures characteristics are detailed in Table 1. Strictures were not passable by the scope in 61.4% (n = 54) of cases and 70.5% (n = 62) were ulcerated. Multiple strictures were observed in 8% (n = 7) of patients. Strictures had a median length of 5.5 cm (IQR, 3.6–10.0) estimated during colonoscopy or when nonpassable with computed tomography scan or magnetic resonance imaging, and 62.5% (n = 55) of patients had symptomatic strictures. Location of strictures was right colon in 12.5%, transverse colon in 14.8%, left colon in 32.8%, sigmoid in 28.4%, and rectum in 9.1% of patients. Details concerning stricture management are presented in Table 1. Stricture-related surgery was needed in 47.7% (n = 42) and the most frequent type of surgery was partial colectomy (n = 19, 45.2%). Endoscopic balloon dilation was performed in 13.6% (n = 12) of patients.

Dysplasia and Cancer Associated With Colonic Stricture

After a median follow-up of 21.5 months (IQR, 5.5–46.5), 7 (8%) among 88 patients with colonic stricture were diagnosed with neoplasia located at the colonic stricture site either at time of stricture diagnosis or during follow-up (Figure). Main characteristics of these patients are presented in Table 2. The median stricture duration at colorectal neoplasia diagnosis was 0.0 month (IQR, 0.0–5.5). Four patients were diagnosed with dysplasia or cancer at stricture diagnosis and the others in the following year. In the 7 patients with malignant stricture, 5 had colonic adenocarcinoma (5.7%) (including 1 mucinous adenocarcinoma), 1 had neuroendocrine carcinoma, and 1 B-cell lymphoproliferative neoplasia. At cancer diagnosis, 5 patients had active colonic inflammation documented with biopsies during the colonoscopy. Three patients died during follow-up (adenocarcinomas, n = 2 and neuroendocrine carcinoma, n = 1), 2 patients were still receiving antineoplastic treatment (adenocarcinomas, n = 2), and patient with B-cells lymphoproliferation was considered in remission. Data were missing for the last patient.Figure Cumulative risk of malignant stricture in patients with Crohn’s disease.

Table 2 Characteristics of Patients With Malignant Stricture

Pathological finding	Moderately to poorly differentiated adenocarcinoma	Mucinous lieberkühnian adenocarcinoma	Dissociated cells adenocarcinoma	Poorly differentiated adenocarcinoma	B-cells lympho-proliferation	Moderately differentiated adenocarcinoma	Neuroendocrine carcinoma	
Median stricture duration at cancer diagnosis (month)	3	0	0	12	8	0	0	
Localization	Left colon	Rectum	Left colon	Rectum	Rectum	Left colon	Right colon	
Occlusive symptoms (yes or no)	Yes	No	Yes	No	No	Yes	Yes	
Passable stricture in colonoscopy (yes or no)	No	No	No	No	No	No	No	
Disease duration at stricture diagnosis (year)	11	27	18	36	21	12	1	
Age at stricture diagnosis (year)	53	58	60	59	32	44	59	
Gender	F	F	F	M	M	F	M	
Patient	1	2	3	4	5	6	7	
F, female; M, male.

Factors Associated With Neoplasia

Neoplastic strictures were diagnosed in older patients than those with benign strictures (median age 58, IQR [48–59] vs median age 39, IQR [30–53] years; P = .03) and with disease evolving for longer (median duration 18 years, IQR [11–24] vs median duration 11 years, IQR [4–19]; P = .27). Obstructive symptoms were observed in, respectively, 57.1% and 11.1% of patients with neoplastic and benign stricture (P < .01). In univariate analysis, obstructive symptoms at stricture diagnosis were associated with neoplastic stricture (odds ratio 10.20, confidence interval 95% [1.96–53.24], P < .01). None associated factor with neoplastic stricture was found in multivariate analysis (Table 3).Table 3 Factors Associated With Malignant Colorectal Stricture During in Univariate and Multivariate Analysis

Variable	Univariate analysis OR 95% CI	P value	Multivariate analysis OR 95% CI	P value	
History of primary sclerosis cholangitis	13.33 [0.74–240.70]	.08			
Age at stricture diagnosis	1.07 [0.99–1.15]	.06	1.06 [1.00–1.13]	.06	
Stricture duration	0.99 [0.96–1.01]	.30			
Disease duration before stricture diagnosis	1.04 [0.97–1.12]	.25			
Occlusive and/or sub-occlusive syndrome	10.22 [1.96–53.24]	<10−2			
Extensive colitis	2.10 [0.24–18.47]	.50			
Ulcerated stricture	0.62 [0.10–3.67]	.60			
Stricture location					
 Left colon	Ref				
 Rectum	5.20 [0.81–33.56]	.08			
 Right colon	0.87 [0.080–9.34]	.91			
CI, confidence interval; OR, odds ratio.

Discussion

The management of inflammatory bowel disease patients with colonic strictures remains a challenge in clinical practice. The neoplastic risk associated with stricture remains poorly known in the era of biologics and modern endoscopy. In our study, including 88 consecutive patients, the prevalence of malignant stricture was 8%. All these neoplastic lesions were diagnosed at stricture diagnosis or in the following year.

This result is higher than reported in recent studies showing a risk of malignant stricture from 0.32% to 3.5%.11, 12, 13, 14,16 The different types of studied populations could explain these differences. Tilmant et al18 included only patients who underwent endoscopic balloon dilatation for colonic stricture. Fumery et al16 included only patients operated for a colonic stricture with preoperative negative endoscopic biopsies. Sonnenberg et al12 only included patients who underwent colonoscopy with endoscopic biopsies from an administrative database. On the other hand, in a referral study including 175 strictures diagnosed between 1959 and 1985, the prevalence of malignant stricture was 6.8%.11

Factors known as associated with malignant colonic strictures are heterogeneous as age, disease duration, short stricture, and absence of active lesion at the time of surgery.11,13 Nevertheless, we did not confirm these findings in our study; disease duration was not significantly associated with cancer risk in multivariate analysis, stricture length could not be analyzed and for most of patients, stricture was described as ulcerated during the colonoscopy. In our study, none factor was associated to malignant stricture in multivariate analysis. Other known risk factors for CRC such as extensive colitis, duration of the disease, and history of primary sclerosis cholangitis were not found as risk factors of cancer.

Among the 7 patients with CRC, diagnosis was made at the time of stricture diagnosis in half of the patients and within the first year for the others. We believe that this result is important for the management of colonic strictures complicating CD in clinical practice. Colonic strictures are considered, since the results of old studies, as a risk factor for CRC, which justifies annual screening endoscopic according to international recommendations. Several hypotheses can be considered: (1) strictures observed are already a neoplastic complication of the colonic inflammatory disease, (2) the stricture itself is a risk factor for cancer on the same site, or (3) the colonic stricture precludes adequate endoscopic surveillance of the whole colon. The fact that all cancers were diagnosed at the time of stricture diagnosis or just after and that none was observed during a median follow-up of 21.5 months argues for the first hypothesis. In Sonnenberg et al12 study, duration of follow-up was not mentioned. In Fumery et al16 study concerning patient with negative biopsies who underwent colonic stricture surgery, median stricture duration was 6.3 months.

We know that per endoscopic biopsies could not be enough to exclude stricture-associated dysplasia or cancer, explaining potential early use of surgery in these patients.16 This risk is however relatively low—2.2%. On the other hand, the absence of longer-term risk of cancer associated with colonic stricture observed in our study is in favor of conservative management in several patients with colonic strictures. In a recent administrative database cohort study, the presence of a colorectal stricture was not independently associated with CRC suggesting for the authors that colonic stricture is a stigma of long-standing active disease rather than an independent risk factor for CRC.19

Given the recent evidence on the risk of cancer associated with colonic strictures in CD, systematic colectomy is probably no longer justified. Factors such as a long disease duration, primary sclerosing cholangitis, a history of dysplasia, and nonpassable and/or symptomatic stricture despite endoscopic dilation tend to argue in favor of surgery—especially if limited resection is possible. Conversely, a conservative approach can be considered after a multidisciplinary case-by-case discussion in patients with low risk of neoplastic complications after a precise endoscopic evaluation with systematic biopsies. According to recent recommendations, when the stricture is nonpassable, extending less than 5 cm, endoscopic balloon dilation should be performed after cross-sectional imaging, to pass and explore the upstream colon and screen for dysplasia.13 If the stricture becomes passable and ulcerations are observed, intensification of medical therapy could be proposed. According to international recommendations and waiting for news studies, close endoscopic surveillance should be done.

Our study has some limitations. We have to recognize missing data inherent to retrospective studies, especially concerning biological and radiological characteristics. Our sample size was not sufficient to identify factors associated with cancer. Nevertheless, our study has numerous strengths. It is one of the largest studies and duration of follow-up was almost 2 years. Importantly, we included consecutive CD patients followed in 3 French referral centers with colonic stricture regardless of their surgery or endoscopic status.

In conclusion, 8% of patients with colonic stricture complicating CD developed CRC. Cancer and stricture were often diagnosed at the same time and we did not report malignant stricture after 1 year of follow-up. These results plead for a conservative management of passable colonic stricture in CD patients after a precise endoscopic evaluation with biopsies in patients at low risk of CRC.

Authors' Contributions:

Thomas Hunaut: Conception and design of the study; generation, collection, assembly, analysis and/or interpretation of data; drafting the manuscript; revision of the manuscript; statistical analysis. Mathurin Fumery: Conception and design of the study; generation, collection, assembly, analysis and/or interpretation of data; drafting the manuscript; revision of the manuscript. Corinne Gower-Rousseau: Conception and design of the study; generation, collection, assembly, analysis and/or interpretation of data; revision of the manuscript. Guillaume Cadiot: Drafting the manuscript; generation, collection, assembly, analysis and/or interpretation of data; revision of the manuscript. Antoine Le Bozec: Generation, collection, assembly, analysis and/or interpretation of data; revision of the manuscript; statistical analysis. All authors approved the final version of the article, including the authorship list.

Conflicts of Interest: These authors disclose the following: Mathurin Fumery has received lecture and consulting fees from Abbvie, MSD, Boehringer, Pfizer, Takeda, Fresenius, Celgene, Gilead, Celltrion, Sandoz, CTMA, Amgen, Biogen, Viatris, Lilly, Celgene, Gilead, Tillots, Galapagos, Janssen, and Ferring. Laurent Peyrin-Biroulet declares consulting fees from AbbVie, Adacyte, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celltrion, CONNECT Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC-Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Norgine, Nordic Pharma, Novartis, OMPharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Par’Immune, Pfizer, Prometheus, Protagonist, Roche, Sanofi, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, Ysopia, Abivax, Samsung, Ventyx, Roivant, and Vectivbio. The remaining authors disclose no conflicts.

Funding: The authors report no funding.

Ethical Statement: The study was approved by local Ethics Committee (MR00429082023, “CHU de Reims”).

Data Transparency Statement: Data available on request from the authors.

Reporting Guidelines: The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, and applicable regulatory requirements.
==== Refs
References

1 Torres J. Mehandru S. Colombel J.F. Crohn's disease Lancet 389 2017 1741 1755 27914655
2 Roda G. Chien Ng S. Kotze P.G. Crohn's disease Nat Rev Dis Primers 6 2020 22 32242028
3 Herrinton L.J. Liu L. Levin T.R. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010 Gastroenterology 143 2012 382 389 22609382
4 Olén O. Erichsen R. Sachs M.C. Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study Lancet Gastroenterol Hepatol 5 2020 475 484 32066530
5 Lutgens M. van Oijen M. van der Heijden G. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies Inflamm Bowel Dis 19 2013 789 799 23448792
6 Torres J. Pineton de Chambrun G. Itzkowitz S. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease Aliment Pharmacol Ther 34 2011 497 508 21692821
7 Maykel J.A. Hagerman G. Mellgren A.F. Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients Dis Colon Rectum 49 2006 950 957 16729218
8 Clarke W.T. Feuerstein J.D. Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments World J Gastroenterol 25 2019 4148 4157 31435169
9 Wijnands A.M. de Jong M.E. Lutgens M.W.M.D. Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis Gastroenterology 160 2021 1584 1598 33385426
10 Friedberg S. Rubin D.T. Intestinal cancer and dysplasia in Crohn's disease Gastroenterol Clin North Am 51 2022 369 379 35595420
11 Yamazaki Y. Ribeiro M.B. Sachar D.B. Malignant colorectal strictures in Crohn's disease Am J Gastroenterol 86 1991 882 885 2058631
12 Sonnenberg A. Genta R.M. Epithelial dysplasia and cancer in IBD strictures J Crohns Colitis 9 2015 769 775 26079724
13 Fumery M. Yzet C. Chatelain D. Colonic strictures in inflammatory bowel disease: epidemiology, complications, and management J Crohns Colitis 15 2021 1766 1773 33844013
14 Goldberg H.I. Caruthers S.B. Nelson J.A. Radiographic findings of the National Cooperative Crohn's Disease Study Gastroenterology 77 1979 925 937 38181
15 Magro F. Gionchetti P. Eliakim R. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders J Crohns Colitis 11 2017 649 670 28158501
16 Fumery M. Pineton de Chambrun G. Stefanescu C. Detection of dysplasia or cancer in 3.5% of patients with inflammatory bowel disease and colonic strictures Clin Gastroenterol Hepatol 13 2015 1770 1775 26001338
17 Silverberg M.S. Satsangi J. Ahmad T. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology Can J Gastroenterol 19 Suppl A 2005 5A 36A
18 Tilmant M. Serrero M. Poullenot F. Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study Clin Res Hepatol Gastroenterol 45 2021 101561
19 Axelrad J.E. Faye A. Slaughter J.C. Colorectal strictures in patients with inflammatory bowel disease do not independently predict colorectal neoplasia Inflamm Bowel Dis 28 2022 855 861 34319381
